论文部分内容阅读
子宫内膜癌是女性生殖系统常见的恶性肿瘤,晚期或复发子宫内膜癌患者往往失去了手术时机,治疗较为棘手,以药物治疗为主,因此药物治疗受到广泛的关注和研究。分子靶向药物是近年新兴的抗肿瘤药物,在一些恶性肿瘤的防治中已经彰显成效。近年晚期或复发子宫内膜癌药物治疗的新策略转向应用针对肿瘤发展特异性生物环节的分子靶向药物,其中一些药物已进入临床研究阶段,并证实在延长患者生存期、缓解症状、提高生活质量及耐受性方面优于传统的化疗。现就分子靶向药物在晚期或复发子宫内膜癌中的应用进展作一综述。
Endometrial cancer is a common malignant tumor of the female reproductive system, patients with advanced or recurrent endometrial cancer often lose the opportunity for surgery, treatment is more difficult to drug-based, drug treatment has received widespread attention and research. Molecular targeted drugs are emerging anti-tumor drugs in recent years, some of the prevention and treatment of malignant tumors has been demonstrated effective. New strategies for the treatment of late-stage or recurrent endometrial cancer in recent years have turned to the use of molecularly-targeted drugs targeted at specific biological aspects of tumor development. Some of these drugs have entered clinical trials and have been shown to prolong patient survival, alleviate symptoms, and improve life Better quality and tolerability than traditional chemotherapy. The progress of application of molecular targeted drugs in advanced or recurrent endometrial cancer is reviewed.